



Publications 2015 de l'Intergruppo Francophone du Myélome (IFM)

Impact of renal impairment on outcomes with lenalidomide and dexamethasone treatment in the FIRST trial, a randomized, open-label phase 3 trial in transplant-ineligible patients with multiple myeloma.

Dimopoulos MA, Cheung MC, Roussel M, Liu T, Gamberi B, Kolb B, Derigs HG, Eom H, Belhadj K, Lenain P, Van der Jagt R, Rigaudeau S, Dib M, Hall R, Jardel H, Jaccard A, Tosikyan A, Karlin L, Bensinger W, Schots R, Leupin N, Chen G, Marek J, Ervin-Haynes A, Facon T. *Haematologica*. 2016 Mar;101(3):363-70. doi: 10.3324/haematol.2015.133629. Epub 2015 Dec 11

Maintenance therapy for multiple myeloma in the era of novel agents. Facon T.

Hematology Am Soc Hematol Educ Program. 2015;2015:279-85. doi: 10.1182/asheducation-2015.1.279

Cost-effectiveness of lenalidomide plus dexamethasone vs bortezomib plus melphalan and prednisone in transplant-ineligible US patients with newly-diagnosed multiple myeloma.

Usmani SZ, Cavenagh JD, Belch AR, Hulin C, Basu S, White D, Nooka A, Ervin-Haynes A, Yiu W, Nagarwala Y, Berger A, Pelligra CG, Guo S, Binder G, Gibson CJ, Facon T. *J Med Econ*. 2016;19(3):243-58. doi: 10.3111/13696998.2015.1115407. Epub 2015 Nov 17

Understanding the role of hyperdiploidy in myeloma prognosis: which trisomies really matter?

Chretien ML, Corre J, Lauwers-Cances V, Magrangeas F, Cleyngen A, Yon E, Hulin C, Leleu X, Orsini-Piocelle F, Blade JS, Sohn C, Karlin L, Delbrel X, Hebraud B, Roussel M, Marit G, Garderet L, Mohty M, Rodon P, Voillat L, Royer B, Jaccard A, Belhadj K, Fontan J, Caillot D, Stoppa AM, Attal M, Facon T, Moreau P, Minvielle S, Avet-Loiseau H. *Blood*. 2015 Dec 17;126(25):2713-9. doi: 10.1182/blood-2015-06-650242. Epub 2015 Oct 29.

Frontline therapy of multiple myeloma.

Moreau P, Attal M, Facon T. *Blood*. 2015 May 14;125(20):3076-84. doi: 10.1182/blood-2014-09-568915. Epub 2015 Apr 2. Review.

Phase 1/2 study of carfilzomib plus melphalan and prednisone in patients aged over 65 years with newly diagnosed multiple myeloma.

Moreau P, Kolb B, Attal M, Caillot D, Benboubker L, Tiab M, Touzeau C, Leleu X, Roussel M, Chateleix C, Planche L, Chiffolleau A, Fortin J, Avet-Loiseau H, Mary JY, Hulin C, Facon T. *Blood*. 2015 May 14;125(20):3100-4. doi: 10.1182/blood-2015-02-626168. Epub 2015 Mar 17.

Health-related quality-of-life in patients with newly diagnosed multiple myeloma in the FIRST trial: lenalidomide plus low-dose dexamethasone versus melphalan, prednisone, thalidomide.

Delforge M, Minuk L, Eisenmann JC, Arnulf B, Canepa L, Fragasso A, Leyvraz S, Langer C, Ezaydi Y, Vogl DT, Giraldo-Castellano P, Yoon SS, Zarnitsky C, Escoffre-Barbe M, Lemieux B, Song K, Bahlis NJ, Guo S, Monzini MS, Ervin-Haynes A, Houck V, Facon T. *Haematologica*. 2015 Jun;100(6):826-33. doi: 10.3324/haematol.2014.120121. Epub 2015 Mar 13.

Role of additional chromosomal changes in the prognostic value of t(4;14) and del(17p) in multiple myeloma: the IFM experience.

Hebraud B, Magrangeas F, Cleyngen A, Lauwers-Cances V, Chretien ML, Hulin C, Leleu X, Yon E, Marit G, Karlin L, Roussel M, Stoppa AM, Belhadj K, Voillat L, Garderet L, Macro M, Caillot D, Mohty M, Facon T, Moreau P, Attal M, Munshi N, Corre J, Minvielle S, Avet-Loiseau H. *Blood*. 2015 Mar 26;125(13):2095-100. doi: 10.1182/blood-2014-07-587964. Epub 2015 Jan 30.

Pomalidomide plus low-dose dexamethasone in multiple myeloma with deletion 17p and/or translocation (4;14): IFM 2010-02 trial results.

Leleu X, Karlin L, Macro M, Hulin C, Garderet L, Roussel M, Arnulf B, Pegourie B, Kolb B, Stoppa AM, Brechiniac S, Marit G, Thielemans B, Onraed B, Mathiot C, Banos A, Lacotte L, Tiab M, Dib M, Fuzibet JG, Petillon MO, Rodon P,

Wetterwald M, Royer B, Legros L, Benboubker L, Decaux O, Escoffre-Barbe M, Caillot D, Fermand JP, Moreau P, Attal M, Avet-Loiseau H, Facon T; Intergroupe Francophone du Myélome (IFM). Blood. 2015 Feb 26;125(9):1411-7. doi: 10.1182/blood-2014-11-612069. Epub 2015 Jan 9.

How I treat extramedullary myeloma.

Touzeau C, Moreau P.

Blood. 2016 Feb 25;127(8):971-6. doi: 10.1182/blood-2015-07-635383. Epub 2015 Dec 17

Comparison of serum free light chain and urine electrophoresis for the detection of the light chain component of monoclonal immunoglobulins in light chain and intact immunoglobulin multiple myeloma.

Dejoie T, Attal M, Moreau P, Harousseau JL, Avet-Loiseau H. Haematologica. 2016 Mar;101(3):356-62. doi: 10.3324/haematol.2015.126797. Epub 2015 Dec 3.

Multiple myeloma: from front-line to relapsed therapies.

Moreau P, Touzeau C. Am Soc Clin Oncol Educ Book. 2015:e504-11. doi: 10.14694/EdBook_AM.2015.35.e504. Review.

Phase II study of bendamustine, bortezomib and dexamethasone as second-line treatment for elderly patients with multiple myeloma: the Intergroupe Francophone du Myelome 2009-01 trial.

Rodon P, Hulin C, Pegourie B, Tiab M, Anglaret B, Benboubker L, Jardel H, Decaux O, Kolb B, Roussel M, Garderet L, Leleu X, Fitoussi O, Chateix C, Casassus P, Lenain P, Royer B, Banos A, Benramdane R, Cony-Makhoul P, Dib M, Fontan J, Stoppa AM, Traullé C, Vilque JP, Pétilion MO, Mathiot C, Dejoie T, Avet-Loiseau H, Moreau P. Haematologica. 2015 Feb;100(2):e56-9. doi: 10.3324/haematol.2014.110890. Epub 2014 Nov 14. No abstract available.

Bortezomib-thalidomide-dexamethasone versus bortezomib-cyclophosphamide-dexamethasone as induction therapy prior to autologous stem cell transplantation in multiple myeloma.

Moreau P, Mary JY, Attal M. Br J Haematol. 2015 Feb;168(4):605-6. doi: 10.1111/bjh.13128. Epub 2014 Sep 19. No abstract available.

Genetics of multiple myeloma: another heterogeneity level?

Corre J, Munshi N, Avet-Loiseau H.

Blood. 2015 Mar 19;125(12):1870-6. doi: 10.1182/blood-2014-10-567370. Epub 2015 Jan 27. Review.